Board Meeting Details

The Board Meeting commenced at 04:30 PM and concluded at 05:06 PM on 09th June, 2026.

Key Approvals

1. Standalone Audited Financial Results: Approved the Standalone Audited Financial Results for the half-year and year ended 31st March, 2026, together with Statement of Assets and Liabilities, prepared in compliance with applicable Accounting Standards.

2. Appointment of Internal Auditor: Appointed M/s. Kunal Dutt & Associates, Practicing Company Secretaries (Membership No.: FCS 8831) as Internal Auditor of the Company from the financial year 2026-27 onwards. The firm is not related to any Director/KMP of the Company.

Financial Results Summary (Year Ended 31st March, 2026)

Profit & Loss Statement (₹ in Lakhs):

  • Total Income: ₹3,119.88
  • Total Expenses: ₹2,581.34
  • Profit Before Tax: ₹538.54
  • Tax Expense: ₹143.43 (Current tax) + ₹16.60 (Deferred tax) = ₹160.03
  • Profit After Tax: ₹411.71
  • Earnings Per Share (Basic & Diluted): ₹5.97

Comparative Figures (Previous Year - Year Ended 31st March, 2025):

  • Profit After Tax: ₹135.56
  • Earnings Per Share: ₹1.96

Half-Year Ended 31st March, 2026 (₹ in Lakhs):

  • Total Income: ₹1,730.67
  • Profit Before Tax: ₹353.45
  • Tax Expense: ₹97.10 (Current tax) + ₹19.80 (Deferred tax) = ₹116.90
  • Profit After Tax: ₹276.15
  • Earnings Per Share: ₹4.00

Balance Sheet Position (As at 31st March, 2026)

Equity and Liabilities (₹ in Lakhs):

  • Share Capital: ₹870.70 (unchanged from previous year)
  • Reserves and Surplus: ₹554.26 (increased from ₹155.33)
  • Total Shareholders' Funds: ₹1,424.96 (increased from ₹1,026.03)
  • Long-term Borrowings: ₹146.32 (decreased from ₹319.27)
  • Short-term Borrowings: ₹769.85 (decreased from ₹784.17)
  • Total Liabilities: ₹2,887.09 (increased from ₹2,618.70)

Assets (₹ in Lakhs):

  • Property, Plant and Equipment: ₹264.91 (net, decreased from ₹283.67)
  • Intangible Assets: ₹5.60 (increased from ₹5.30)
  • Inventories: ₹621.22 (decreased from ₹677.72)
  • Trade Receivables: ₹1,612.81 (increased from ₹1,069.32)
  • Cash and Cash Equivalents: ₹59.24 (decreased from ₹123.97)
  • Total Assets: ₹2,887.09 (increased from ₹2,618.70)

Cash Flow Statement (Year Ended 31st March, 2026)

  • Cash Flow from Operating Activities: ₹281.46 lakh
  • Cash Flow from Investing Activities: (₹5.78) lakh
  • Cash Flow from Financing Activities: (₹340.41) lakh
  • Net Decrease in Cash: (₹64.73) lakh
  • Cash at Beginning: ₹123.97 lakh
  • Cash at End: ₹59.24 lakh

Significant Notes to Financial Results

1. The company is engaged exclusively in the Wholesale Trade of Pharmaceuticals, hence no segment reporting is required under AS 17.

2. No investor complaints were received/pending as on 31st March, 2026.

3. The company is exempt from adopting IND AS as per MCA notification dated 16th February, 2015, for companies listed on SME platform.

4. The company was listed on Bombay Stock Exchange's SME Platform on 19th May 2026, subsequent to the reporting period.

5. Figures of previous period/year have been regrouped/recast for comparability.

Additional Compliance Declaration

The company submitted a separate declaration confirming that the Auditor's Report on Standalone Financial Statements for the Half-Year and Year ended 31st March, 2026 is unmodified and without any qualification, pursuant to Regulation 33(3)(d) of SEBI Listing Regulations.

Dissemination of Information

The financial results are being disseminated on the company's website at https://www.goldlinepharma.in.